Pharma IQ Members

Informatics

Find out which informatics are right for your lab. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in pharmaceutical, biotech and life science laboratories to exchange ideas on best practice and share case studies on laboratory innovation and automation within the area.

Contributor: Kate Torchilin
Posted: 28/04/2016
default profile icon
Biomarkers are an essential part of such a translational effort and are critical to understanding human disease. Human biospecimens can provide a bridge between the early discovery and molecular mechanism of the disease and the clinical utility. Commonly, human biospecimens are used to: Full Article »
Contributor: Gerald Clarke
Posted: 24/03/2014
The informatics landscape is changing quickly and innovation could be the key to increasing efficiency. Jeff Hurst, Senior Scientist at the Hershey's Company talks us through these changes and how the industry is moving away from robots towards more innovative methods including mobile apps. He also talks about the dangers of becoming overly ' Full Podcast »
Contributor: Andrew Love
Posted: 10/09/2014
Andrew Love
In the final article in his serialisation series, Andrew Love looks at what needs to be done to commence the development of your strategy and implementation of your solutions. Andrew outlines the challenges you are likely to face such as identifying and interpreting the emerging and evolving legislation or Understanding the immature and evolving solution supply base and selecting appropriate implementation partners. He outlines solutions to these problems to clear your path to serialisation implementation Full Column »
Contributor: Chanice Henry
Posted: 28/04/2016
Chanice Henry
With a view to contribute to the industry’s ongoing progression, Pharma IQ collates the lessons learnt by hospitals during the implementation of UDIs for medical devices and how the conduct of manufacturers and hospitals could be altered to not just optimize this project’s roll out but to avoid incurring any detriment. Full Whitepaper »